A re-start of DirectGene Inc., Advagen Inc. will marry its gene therapy for prostate cancer to newly in-licensed IP covering small peptide ligands with an affinity for the PSMA receptor. The company believes its new platform will greatly enhance adenovirus targeting and facilitate systemic delivery of gene therapies for a variety of cancers.
2661 Riva Road
Building 500, Suite 520
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The osteogenesis imperfecta drug stumbled in a second interim analysis.
Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
